Author/Authors :
Cheneau، نويسنده , , Edouard and Canos، نويسنده , , Daniel and Kuchulakanti، نويسنده , , Pramod K. and Rha، نويسنده , , Seung-Woon and Satler، نويسنده , , Lowell F. and Suddath، نويسنده , , William O. and Kent، نويسنده , , Kenneth M. and Pichard، نويسنده , , Augusto D. and Waksman، نويسنده , , Ron، نويسنده ,
Abstract :
Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.
